文献速递肾移植

术前卡非佐米联合鲁利珠单抗脱敏延长致敏非人灵长类模型移植物存活

Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model.
PubMed 文献 · Kidney Int · 2020-09-06

该研究在5对最大MHC错配的非人灵长类中,先经两次皮肤移植致敏,再随机接受卡非佐米联合鲁利珠单抗脱敏或不脱敏,随后行肾移植。脱敏组供者特异性抗体、滤泡辅助T细胞和增殖性B细胞显著减少,移植物存活显著延长,但最终均发生抗体介导排斥。

要点

  • 卡非佐米联合鲁利珠单抗可显著降低致敏动物供者特异性抗体水平。
  • 脱敏组移植物存活时间显著长于对照组(MST 5.8±4.0 vs 64.8±36.3,p<0.05)。
  • 所有脱敏动物最终仍发生抗体介导排斥和移植物衰竭。

核心结论

  • 卡非佐米联合鲁利珠单抗脱敏通过短暂控制生发中心并将免疫系统转向更初始表型,改善致敏非人灵长类同种异体移植物存活。

研究设计与样本

  • 研究纳入5对最大MHC错配的非人灵长类,经两次序贯皮肤移植相互致敏。
  • 每对中个体随机接受每周一次卡非佐米(27mg/m2 IV)联合鲁利珠单抗(12.5mg/kg SC)共4周脱敏或不脱敏。
  • 随后所有动物接受来自既往皮肤供者的维持生命肾移植,并采用兔抗胸腺细胞球蛋白诱导及他克莫司、霉酚酸酯、甲泼尼龙维持免疫抑制。

主要发现

  • 脱敏组供者特异性抗体、淋巴结滤泡辅助T细胞(CD4+PD-1+ICOS+)和增殖性B细胞(CD20+Ki67+)显著减少。
  • 脱敏后调节性T细胞(CD4+CD25+CD127lo)频率维持,循环初始CD4 T细胞(CCR7+CD45RA+)和初始B细胞(IgD+CD27-CD20+)频率增加。
  • 脱敏组移植物存活显著延长(MST=5.8±4.0 vs 64.8±36.3;p<0.05),抗体介导排斥评分低于对照组。
  • 所有脱敏动物最终均发生抗体介导排斥和移植物衰竭。

临床怎么用

  • 该方案可能转化至临床,用于改善高度致敏移植患者的结局。

局限性

  • 脱敏方案仅实现移植物存活的暂时延长,所有动物最终仍发生抗体介导排斥和移植物衰竭。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sensitized patients are difficult to transplant due to pre-formed anti-donor immunity. We have previously reported successful desensitization using carfilzomib and belatacept in a non-human primate (NHP) model. Here we evaluated selective blockade of the co-stimulatory signal (CD28-B7) with Lulizumab, which preserves the co-inhibitory signal (CTLA4-B7). Five maximally MHC-mismatched pairs of NHPs were sensitized to each other with two sequential skin transplants. Individuals from each pair were randomized to either desensitization with once-weekly Carfilzomib (27mg/m2 IV) and Lulizumab (12.5mg/kg SC) over four weeks, or no desensitization (Control). NHPs then underwent life-sustaining kidney transplantation from their previous skin donor. Rhesus-specific anti-thymocyte globulin was used as induction therapy and immunosuppression maintained with tacrolimus, mycophenolate, and methylprednisolone. Desensitized subjects demonstrated a significant reduction in donor-specific antibody, follicular helper T cells (CD4+PD-1+ICOS+), and proliferating B cells (CD20+Ki67+) in the lymph nodes. Interestingly, regulatory T cell (CD4+CD25+CD127lo) frequency was maintained after desensitization in addition to increased frequency of naïve CD4 T cells (CCR7+CD45RA+) and naïve B cells (IgD+CD27-CD20+) in circulation. This was associated with significant prolongation in graft survival (MST = 5.8 ± 4.0 vs. 64.8 ± 36.3; p<0.05) and lower antibody-mediated rejection scores compared to control animals. However, all desensitized animals eventually developed AMR and graft failure. Desensitization with CFZ and Lulizumab improves allograft survival in allosensitized NHPs, by transient control of the germinal center and shifting of the immune system to a more naive phenotype. This regimen may translate into clinical practice to improve outcomes of highly sensitized transplant patients.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Schroder PM, Schmitz R, Fitch ZW, et al. Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model. Kidney Int. 2020. PMID: 32898569. doi:10.1016/j.kint.2020.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。